Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDIV 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 250Leukemia 186Lymphoma 137Leukemia, Myeloid, Acute 103Burkitt Lymphoma 90Myelodysplastic Syndromes 79Lymphoma, Non-Hodgkin 65Breast Neoplasms 60Lymphoma, Large B-Cell, Diffuse 59Leukemia, Lymphocytic, Chronic, B-Cell 49Lymphoma, Mantle-Cell 47Hodgkin Disease 47Graft vs Host Disease 46Lymphoma, Follicular 45Leukemia, Myeloid, Accelerated Phase 45Multiple Myeloma 39Leukemia, Myeloid, Chronic-Phase 39Congenital Abnormalities 39Myeloproliferative Disorders 38Blast Crisis 38Leukemia, Myelomonocytic, Chronic 37Leukemia, Biphenotypic, Acute 35Recurrence 34Lymphoma, Large-Cell, Immunoblastic 33Lymphoma, B-Cell, Marginal Zone 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 30Osteosarcoma 29Primary Myelofibrosis 27Neoplasms, Plasma Cell 25Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25

Interventions

rozanolixizumab 11efgartigimod alfa 10zilucoplan 8Prednisone 8Cyclophosphamide 8ravulizumab 7Rituximab 7Pyridostigmine Bromide 7telitacicept 6fludarabine 6Tacrolimus 6Mycophenolic Acid 6eculizumab 5Immunoglobulins, Intravenous 5Hizentra 4Azathioprine 4Steroids 3HBM9161 3Data Collection 3Amifampridine 3thymoglobulin 2inebilizumab 2Thymectomy 2Prednisolone 2Methylprednisolone 2Methotrexate 2Exercise 2Diagnostic Self Evaluation 2Blood Specimen Collection 2tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myasthenia Gravis × Methotrexate × Clear all
NCT04101578 2021-08-23

Clinical Prognosis and Progression of Myasthenia Gravis Patients

Da, Yuwei, M.D.

Unknown
2,000 enrolled

Myasthenia Gravis

NCT00814138 2016-05-26

Efficacy of Methotrexate in Myasthenia Gravis

University of Kansas Medical Center

Phase 2 Completed
50 enrolled 15 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡